DURECT Corp (NASDAQ: DRRX) reported Q2 EPS of $0.07, $0.07 better than the analyst estimate of $0.00. Revenue for the quarter came in at $25.8 million versus the consensus estimate of $11.48 million.

"We continued to make progress in our clinical programs investigating DUR-928, our lead epigenetic regulator, during the second quarter. We were pleased to report positive topline data from our Phase 1b NASH trial and we look forward to presenting additional data from the trial at a future scientific meeting," stated James E. Brown, D.V.M., President and CEO of DURECT. "We also initiated a Phase 2 trial of DUR-928 in COVID-19 patients with acute liver or kidney injury and are finalizing our preparations to initiate the Phase 2b trial with DUR-928 in alcoholic hepatitis in the upcoming months. The review of our New Drug Application (NDA) for POSIMIR is also ongoing and we continue to respond to the Agency\'s requests for information."

For earnings history and earnings-related data on DURECT Corp (DRRX) click here.